New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to
most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease.
Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes,
the measurement and manipulation of these small nucleotides in RCC patients may provide yet
another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the
current literature on the role of microRNAs in RCC development and progression emphasizing the interaction
of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance
in renal cancer.
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma,
vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Rights & PermissionsPrintExport